News Sentiment

TRDA sentiment intelligence

Entrada Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.89 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-0.4% over one week, -2.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend inactive -2.8% over four weeks
Fair value -43.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 32
Negative 14

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
TradingView 6
Stock Traders Daily 5
TradingKey 4
simplywall.st 4
The Globe and Mail 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 21
Analyst action 4
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Stock Titan Direct company coverage

Rare disease trial tests DMD treatment with once-every-six-week dosing

Entrada Therapeutics announced that an independent Data Monitoring Committee recommended escalating the dose of ENTR-601-45 to 10 mg/kg for Cohort 2 in its Phase 1/2 ELEVATE-45-201 study for Duchenne muscular dystrophy. All eight participants from Cohort 1, who received 5 mg/kg,

Tone
Positive 62/100
Event
Market update
Published
02 Jun 2026 10:39
Source
Stock Titan